Shots:

• The P-Ib/II (EV-103/KEYNOTE-869) cohort K trial evaluating Padcev + Merck’s Keytruda in patients with unresectable LA or mUC who are ineligible to receive cisplatin-based CT
• The 1EPs of the cohort K study showed a 64.5% confirmed ORR as per BICR, m-DOR was not reached in patients treated with enfortumab vedotin and pembrolizumab. The 2EPs include ORR per investigator assessment; DoR, DCR, PFS as per BICR and investigator assessment; OS; and assessment of safety
• The results were consistent with prior reported efficacy and safety results of the EV-103 dose-escalation cohort and expansion Cohort A. Additionally, the companies plan to discuss the results with regulatory authorities

Ref: Bussinesswire | Image: Seagen